Oncogenic H-Ras requires farnesylation for its transforming activity. Lovastatin inhibits both protein farnesylation and geranylgeranylation by decreasing cellular pools of farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP), respectively. Use of lovastatin as a chemotherapeutic agent has been precluded by its signi®cant cytotoxic eects. In this report, we describe a novel approach utilizing a combination of lovastatin and geranylgeraniol (GGOH) to potentiate the ability of lovastatin to block oncogenic H-Ras signaling and concomitantly rescue lovastatin toxicity. GGOH co-treatment with lovastatin enhances inhibition of oncogenic H-Ras processing and constitutive activation of mitogen-activated protein kinase (MAPK), and preserves the processing of geranylgeranyltransferase (GGTase) I and GGTase II protein substrates. Moreover, co-treatment with GGOH signi®cantly (15-fold) attenuates the cytotoxic eects of lovastatin as well as prevents lovastatin-induced cell rounding. These results demonstrate that GGOH potentiates the antioncogenic/anti-signaling activity of lovastatin while antagonizing its cytotoxicity. These opposing eects are due to a GGOH metabolite that serves simultaneously as a potent inhibitor for farneslyltransferase as well as a substrate for GGTases I and II.
Introduction
The mevalonic acid (MVA) pathway is responsible for the biosynthesis of cholesterol and isoprenoid intermediates such as geranylgeranylpyrophosphate (GGPP) and farnesylpyrophosphate (FPP) . Two sites in the MVA pathway have been cited to be of particular importance: the synthesis of MVA by hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, an early step thought to be the major point of regulation, and the so-called`branch-point' of FPP metabolism (Brown and Goldstein, 1980; Sabine, 1983; reviewed in GruÈ nler et al., 1994) . FPP is the last common intermediate in the pathway and is the substrate for a number of dierent enzymes that catalyze committed steps in branching pathways leading to the biosynthesis of cholesterol, ubiquinone, dolichol, as well as isoprenylated proteins and hemes. GGPP synthase, one of the branch-point enzymes, catalyzes the condensation of FPP and isopentenyl pyrophosphate to form GGPP. GGPP and FPP are utilized by geranylgeranyltransferases (GGTases I and II), and farnesyltransferase (FTase), respectively, for posttranslational isoprenylation of proteins on carboxyl terminal cysteine residues (reviewed in GruÈ nler et al., 1994; Maltese, 1990; Casey, 1992) . FTase and GGTase I prenylate proteins with carboxyl termini that end with a CAAX box where C=cysteine, A=aliphatic, and X=any amino acid. FTase prefers X as a serine or methionine whereas GGTase I prefers X as a leucine or isoleucine. GGTase II prenylates proteins that end in XXCC and XCX where X is any amino acid. For several proteins, isoprenylation is essential for proper intracellular localization and biological function (Holtz et al., 1989; Fukada et al., 1990; Der and Cox, 1991; Hori et al., 1991; Inglese et al., 1992) . In contrast to FPP, GGPP is currently known to be utilized only for protein geranylgeranylation and possibly ubiquinone biosynthesis (ViganoÁ et al., 1995) .
Geranylgeranylated proteins and farnesylated proteins appear to comprise distinct, but overlapping sets of proteins, with the former being greater in number than the latter (Epstein et al., 1990; Farnsworth et al., 1990) . Many of these proteins have been shown to play essential roles in signal transduction pathways and some have been implicated in malignant transformation. For example, the geranylgeranylated guanine nucleotide-binding proteins Rho and Rac have recently been shown to be critical players in regulating not only the organization of the actin cytoskeleton (Nobes and Hall, 1995) but also the progression of the cell cycle through G 1 (Olson et al., 1995) . In addition, Ras, another family of guanine nucleotide-binding proteins, control normal cell growth (Mulcahy et al., 1985) and dierentiation (Bar-Sagi and Feramisco, 1985) and, when mutated, can produce malignant transformation (Reddy et al., 1982) . The Ras family of proteins serve as transducers of extracellular signals from receptor tyrosine kinases to the nucleus (McCormick, 1993) . Their stimulation by these receptors results in the activation of several growth-related pathways including a cascade of mitogen-activated protein kinases (MAPKs) such as Raf, MEK and ERK (McCormick, 1993) , the latter of which can translocate to the nucleus and regulate the activity of some transcription factors. In some human cancers, Ras is GTP-locked and constitutively activates the MAPK cascade. The ability of Ras to cause cancer requires its attachment to the plasma membrane which is mediated by prenylation (Der and Cox, 1991; Kato et al., 1992) . The prenylation of Ras in vitro exhibits a preference for farnesylation (James et al., 1995) . Furthermore, although the prenylation of K B -Ras in vivo is, at present, uncertain (Casey et al., 1989; , H-Ras has been shown to require farnesylation for its cancer-causing activity (Hancock et al., 1989; Seabra et al., 1991; . Moreover, in nude mice, inhibitors of FTase are eective at suppressing the growth of tumor cells possessing oncogenic H-or K-Ras .
Lovastatin, a potent competitive inhibitor of HMGCoA reductase (Alberts, 1988) , signi®cantly reduces not only the biosynthesis of the end-product cholesterol, for which it is used clinically (Illingworth and Bacon, 1989) , but also depletes the intracellular pools of GGPP and FPP, resulting in the inhibition of protein geranylgeranylation and protein farnesylation (Leonard et al., 1990) . We have recently shown that lovastatin disrupts early signaling events such as tyrosine phosphorylation levels of the PDGF receptor and its association with PI-3-kinase (McGuire et al., 1993) . Moreover, lovastatin arrests cultured cells predominantly in the G 1 phase of the cell cycle and produces a characteristic rounded morphology (Quesney-Huneeus et al., 1979; Sinensky and Logel, 1985; Fenton et al., 1992) . Lovastatin has also been found to inhibit tumor growth of cells expressing oncogenic H-Ras in nude mice, but at doses that blocked tumor growth, lovastatin was extremely toxic and some animals died (Sebti et al., 1991) . It is not known whether inhibition of protein farnesylation and/or protein geranylgeranylation, or the reduction in levels of some other endproduct of the MVA pathway, are responsible for lovastatin's toxicity.
In this report, we describe the use of lovastatin treatment of cells in conjunction with geranylgeraniol (GGOH) as a novel approach for selectively inhibiting oncogenic H-Ras processing and signaling while rescuing cells from lovastatin toxicity. Our mechanistic investigations lead to a model where GGOH is converted to a metabolite which concomitantly synergizes with lovastatin to inhibit protein farnesylation and which serves as a substrate for geranylgeranyltransferases to reverse inhibition of protein geranylgeranylation.
Results

GGOH potentiates the ability of lovastatin to inhibit oncogenic H-Ras processing and constitutive activation of MAPK
The eects of GGOH on lovastatin inhibition of protein farnesylation were investigated in NIH3T3 cells transformed with an oncogenic, GTP-locked mutant of HRas-CVLS (an FTase substrate). NIH3T3 cells transformed with oncogenic H-Ras-CVLL (mutated at its CAAX box to become a GGTase I substrate) were treated in parallel and served as a control exhibiting processing that is geranylgeranylation-dependent. Cells were treated with lovastatin and GGOH alone or in combination, and the extent of oncogenic H-Ras processing, as well as its ability to stimulate constitutively MAPK, were assessed. After 2 days of treatment, the cells were harvested and lysed and the lysate proteins subsequently separated by SDS ± PAGE and immunoblotted with anti-Ras or anti-MAPK antibodies as described under Materials and methods. Cells treated with vehicle or GGOH alone exhibited only the processed form of Ras. Oncogenic H-Ras constitutively activates MAPK and, therefore, both the active (hyperphos-phorylated) and inactive (hypophosphorylated) forms of MAPK are observed in control cells ( Figure 1a, lanes 1 and 5) . Treatment of cells with GGOH alone had no eect on the processing or signaling of either H-Ras-CVLS or H-Ras-CVLL (Figure 1a , lanes 3 and 7). Lovastatin inhibited the processing of both HRas-CVLS and H-Ras-CVLL and inhibited the activation of MAPK slightly in H-Ras-CVLS-transformed cells and completely in H-Ras-CVLL-transformed cells ( Figure 1a , lanes 2 and 6). GGOH enhanced greatly the ability of lovastatin to inhibit Ras-CVLS farnesylation while it restored Ras-CVLL geranylgeranylation ( Figure  1a , lanes 4 and 8). Furthermore, in the presence of GGOH, lovastatin blocked oncogenic activation of MAPK in Ras-CVLS-transformed cells, whereas, in Ras-CVLL-transformed cells, lovastatin was not able to inhibit MAPK activation (Figure 1a ). The ability of GGOH to enhance the inhibition of oncogenic H-Ras-CVLS processing was concentration-dependent as well as synergistic. As shown in Figure 1b When the same nitrocellulose membrane was reprobed with an antibody against Rap1A, the processing of this endogenous geranylgeranylated protein was observed to be signi®cantly inhibited at 5 mM and 15 mM lovastatin ( Figure 1b , lanes 9 and 13), but was restored upon cotreatment with GGOH at concentrations as low as 7.5 mM (lanes 10 and 14). Quantitative anlaysis of three independent experiments demonstrated that while 15 mM lovastatin inhibited H-Ras processing 54% and Rap1A processing 93%, co-treatment with 15 mM GGOH further reduced levels of processed oncogenic H-Ras (80% inhibition) while processing of Rap1A was completely restored (data not shown). Statistical analysis of the data obtained from these experiments demonstrated that the enhanced inhibition of H-ras processing eected by lovastatin/GGOH co-treatment is statistically dierent from that achieved by using lovastatin alone (P50.01 using a Student's two-tailed paired t-test). Hence, by employing this co-treatment with cells that express constitutively activated H-Ras, the processing and signaling of this oncoprotein can be potently inhibited without aecting the processing/ function of geranylgeranylated proteins.
Geranylgeraniol (GGOH) rescues lovastatin-induced cell rounding, cytoxicity and inhibition of processing of geranylgeranylated proteins
Although lovastatin at high enough concentrations (415 mM) could be used to achieve signi®cant inhibition of oncogenic H-Ras processing and signaling, this also produced signi®cant cell rounding and cytotoxicity. We next determined the extent to which GGOH might alleviate lovastatin-induced cytotoxicity in H-Rastransformed NIH3T3 cells. Figure 2A illustrates the characteristic rounded cell morphology produced by treatment of cells with lovastatin alone as well as the complete prevention of this change by co-treatment with GGOH. The ability of GGOH to attenuate lovastatin cytoxicity was assessed by plating cells in 96-well plates and then treating with various concentrations of lovastatin alone or in combination with GGOH as described under Materials and methods. Figure 2B shows that while lovastatin produced cytoxicity in HRas-transformed 3T3 cells with an IC 50 of 8 mM, cotreatment with GGOH (15 mM) signi®cantly attenuated lovastatin cytotoxicity, increasing the IC 50 by 15-fold. The ability of GGOH to alleviate lovastatin cytotoxicity could be due to a replenishing of either protein geranylgeranylation or ubiquinone (ViganoÁ et al., 1995; Fenton et al., 1992) . The ability of ubiquinone to reverse lovastatin toxicity was directly tested in the identical system described above for GGOH and was found to have no eect on preventing lovastatin toxicity (data not shown). Thus, the inhibition of processing/function of protein substrates for GGTases may be the primary cause for lovastatin cytotoxicity. Rho and Rac proteins, both of which are geranylgeranylated by GGTase I, have been demonstrated to regulate cytoskeleton organization and to play a pivotal role in maintaining cellular shape (Nobes and Hall, 1995) . Thus, it would seem likely that the processing and function of these proteins, like that of Rap1A, are preserved in cells co-treated with lovastatin and GGOH. Although the ability of GGOH to allow recovery of processing for GGTase protein substrates in lovastatin-treated cells might be expected and was implied by previous work (Crick et al., 1994) , demonstration of this had not been previously reported. To further investigate the eect of GGOH on the processing of GGTase protein substrates in lovastatin-treated cells, cells were treated with lovastatin and GGOH alone and in combination and the processing of Rap1A, RhoB (a substrate for GGTase I reported to be geranylgeranylated or farnesylated (Adamson et al., 1992) ) and Rab5 (a substrate for GGTase II) was assessed. As shown in Figure 3 , the inhibition by lovastatin of the processing of these three geranylgeranylated proteins was reversed in cells cotreated with lovastatin and GGOH. However, the processing of H-Ras was further inhibited. (B) cells were plated into 96-well plates (10 000 cells/well) and the following day were treated with various concentrations of lovastatin (0 ± 300 mM) in the presence and absence of 15 mM GGOH. After 4 days, medium was removed from cells and replaced with fresh medium containing 1 mg/ml MTT for 3 h. The number of viable cells was determined by the MTT assay described under Materials and methods. Data are representatiave of two independent experiments Finally, to assess the eect of GGOH co-treatment on the processing of all GGTase I protein substrates in NIH3T3 cells we used a novel approach. Cells were treated with lovastatin (50 mM) and GGOH (25 mM) alone or in combination, harvested and cytosolic fractions prepared and used as a source of protein substrates in an in vitro GGTase I assay as described under Materials and methods. As shown in Figure 4 , the cytosolic fractions obtained from cells treated with vehicle or GGOH alone contained no unprocessed proteins capable of serving as substrates in the in vitro assay (lanes 1 and 2) . However, the cytosolic fractions from lovastatin-treated NIH3T3 cells contained several protein substrates for GGTase I, as demonstrated by the pro®le of tritium-labeled geranylgeranylated proteins ranging from 21 ± 29 kDa that was detected using this assay (Figure 4, lane 3) . When the assay was performed on the cytosolic fractions from NIH3T3 cells co-treated with lovastatin and GGOH, all of the protein substrates for GGTase I (detected in the cytosolic fractions from lovastatin-treated cells) were observed to be signi®cantly reduced (Figure 4 , lane 4). In longer exposures, a few other bands of higher and lower molecular weight appeared in the lane containing cytosol from lovastatin-treated cells, but these also were not detected in the cytosol from cells co-treated with lovastatin and GGOH (data not shown). Thus, this novel approach demonstrates that GGOH is converted to a form capable of rescuing the processing of virtually all proteins that are geranylgerantylated by GGTase I in the cell.
Metabolic labeling of proteins using [ 3 H]GGOH
In order to con®rm that GGOH was being used as a metabolic source for protein prenylation in mouse ®broblasts and to investigate the metabolic fate of GGOH in the cell, H-Ras-CVLS-transformed NIH3T3 cells were treated with [ 3 H]GGOH and 20 mM lovastatin for various lengths of time and the cellular lipids and the delipidated proteins subsequently analysed (see Materials and methods). As shown in Figure 5 , a pattern of labeled proteins (MW range of 21 ± 29 kDa) resembling that obtained for small G proteins was observed. Optimal metabolic labeling of protein was found to occur when unlabeled GGOH was added such that the ®nal concentration was increased from 0.6 mM ([ 3 H]-GGOH alone) to 5.0 mM (Figure 5 ; compare lanes 1 and 2), and when cells were pre-treated overnight with 20 mM lovastatin prior to metabolic labeling ( Figure 5 ; compare lanes 2 and 3). These results suggest that GGOH is being metabolically converted by mouse ®broblasts to an activated form and used for protein geranylgeranylation. In order to assess whether this form is GGPP itself, thin-layer chromatogaphy (TLC) was performed on the lipid extracts of cells labeled for various lengths of time with Figure 2A were harvested, lysed, and whole cell lysate protein (50 mg) was electrophoresed and immunoblotted for Ras, Rap1A, RhoB, and Rab5 using appropriate antibodies as described in Figure 6, lane 3) . Since a signi®cant pool of intracellular GGPP would be expected to be required to inhibit FTase (and, therefore, H-Ras processing) within lovastatin-treated cells (see Discussion below), this should have been easily detected in our system. Hence, these data suggest that the GGOHderived metabolite that is responsible for both the restoration of protein geranylgeranylation, as well as for further inhibition of H-Ras processing, is not GGPP. Further investigation is required to isolate and identify the active GGOH metabolite.
Discussion
The results presented herein clearly demonstrate that GGOH potentiates the anti-oncogenic/anti-signaling activity of lovastatin while antagonizing its cytotoxic eects. The data suggest that inhibition of H-Ras farnesylation and restoration of protein geranylgeranylation, respectively, are responsible for these two opposing eects of GGOH. The fact that GGOH had no apparent eect on protein prenylation in the absence of lovastatin (Figures 1, 3 and 4) strongly suggests that it acts to replenish a metabolite that inhibits FTase and that is a substrate for GGTases I and II. While the identity of the metabolite is not known, our results suggest that a GGOH derivative other than GGPP was formed and was responsible for restoring geranylgeranylation and further inhibiting farnesylation. Furthermore, it is interesting to note that this metabolite can be used as a substrate by two dierent GGTases, as indicated by the preservation of the processing for speci®c protein substrates (Rap1A and RhoB for GGTase I and Rab5 for GGTase II; see Figure 3 ). In addition, it was previously demonstrated that when [ 3 H]GGOH metabolically-labeled proteins were subjected to Pronase E digestion, a labeled product that was chromatographically identical to geranylgeranyl-cysteine was released (Crick et al., 1994) . By achieving the selective restoration of protein geranylgeranylation, not only could cell morphology be maintained at the same phenotype as control cells (Figure 2A ), but much of the cytotoxic eect of lovastatin could be alleviated ( Figure 2B ). The maintenance of cell shape as well as cell cycle progression through G 1 might be expected since these cellular processes have recently been shown to be regulated by geranylgeranylated proteins (Rho and Rac; see Nobes and Hall, 1995; and Olson et al., 1995) . Hence, taking all of these results together, GGOH potentiates the inhibitory eect of lovastatin on protein farnesylation while preserving the cell from the deleterious eects of a 3 H]GGOH (30 mCi/ml) in the presence of 20 mM lovastatin and in the absence (lane 1) or the presence (lanes 2 ± 3) of 4.4 mM unlabeled GGOH. In addition, the eect of pre-treating cells overnight with 20 mM lovastatin prior to metabolic labeling was also assessed (lane 3; see Materials and methods). Equivalent proportions of each sample were applied to SDS ± PAGE. Lanes 1 ± 3 contained 8100 c.p.m., 27 900 c.p.m. and 40 000 c.p.m., respectively. Fluorography was performed on the dried gel using a 9-day exposure at 7808C. Data are representative of four independent experiments block on protein geranylgeranylation. These results, therefore, raise the possibility of using a combination of lovastatin/GGOH as a chemotherapeutic regimen against Ras-dependent human tumors. Further investigation of the eects of this co-treatment on human tumor growth in nude mice is needed to assess this possibility.
Based on the results presented here, we have proposed a model depicting the mechanism by which GGOH confers to lovastatin a selective and enhanced ability to inhibit protein farnesylation and subsequent MAPK activation (Figure 7 ). As discussed above, GGOH is suggested to be taken up and converted by cells to an activated form (designated GGX in Figure  7 ) which serves as the geranylgeranyl donor for protein prenylation catalyzed by GGTases I and II (only GGTase I is depicted in Figure 7) . Moreover, GGX is proposed to competitively inhibit FPP from the active site of FTase, further inhibiting oncogenic H-Ras processing. Previous work demonstrated that GGPP can bind to the active site of FTase with a similar anity to that of FPP but cannot be used as a substrate for protein prenylation (Reiss et al., 1992) . Moreover, we have observed in vitro that GGPP inhibits FTase with an IC 50 of 5 mM (data not shown). Thus, in the presence of lovastatin, endogenous pools of FPP are low and GGX can act to potently inhibit FTase (Figure 7 ): in the absence of lovastatin, no inhibition of H-Ras processing is observed since the levels of GGX formed are not high enough to compete out endogenous FPP from the FTase active site (Figures 1 and 3) . Therefore, the novel approach described in this manuscript is a powerful tool for selectively blocking oncogenic H-Ras signaling while sparing cells from lovastatin cytotoxicity due to inhibition of protein geranylgeranylation.
Materials and Methods
Cell culture
NIH3T3 mouse ®broblasts (ATCC) were maintained in Dulbecco's modi®ed Eagles medium (DMEM) supplemented with 10% fetal bovine serum and 1% Pen-Strep (Life Technologiess Inc.). NIH3T3 cells transfected with the oncogene encoding H-Ras-CVLS(12R) or H-Ras-CVLS(61L) or with the empty vector (pZIPneo) were kind gifts from Dr Channing Der and Dr Adrienne Cox (University of North Carolina, Chapel Hill) and were maintained in DMEM supplemented with 10% calf serum, 1% Pen-Strep and 400 mg/ml G418.
Immunoblotting to assess protein processing and MAP kinase activation Cells were seeded into 100 mm plates (8.0610
5 ± 1.0610 6 / plate) on day 0 such that the following day they were 50 ± 70% con¯uent. Cells were treated twice (days 1 and 2) with vehicle (10 mM DTT in DMSO) or concentrations of lovastatin and/or GGOH as indicated in the ®gure legends. On day 3, cells were harvested in ice cold PBS, pH 7.5, pelleted and lysed in 50 mM HEPES, pH 7.5, 10 mM NaCl, 1% Triton X-100, 10% glycerol, 5 mMMgCl 2 , 1 mM EGTA, 25 mg/ml leupeptin, 2 mM Na 3 VO 4 , 10 mg/ml soybean trypsin inhibitor, 10 mg/ml aprotinin and 6.4 mg/ml phosphatase substrate. After clearing the lysates (14 000 r.p.m., 48C, 10 min), equivalent amounts of protein were applied to SDSpolyacrylamide gels (12.5% for protein processing; 15% for MAP kinase), separated by electrophoresis, and subsequently transferred to nitrocellulose ®lters. Filters were blocked with 5% non-fat dry milk in PBS, 0.1% Tween-20 (PBS-T) and then probed with either anti-Ras (Y13-238 or Y13-259, ATCC), anti-Rap1A (Santa Cruz Biotechnology, Santa Cruz, CA), anti-RhoB (Santa Cruz Biotechnology, Santa Cruz, CA), anti-Rab5 (Transduction Laboratories, Lexington, KY), or anti-MAP kinase (erk2, UBI, Lake Placid, NY) antibodies in 3% non-fat dry milk in PBS-T. Positive antibody reactions were detected using appropriate horseradish peroxidase-conjugated antibodies (Oncogene Science and Jackson ImmunoResearch Laboratories Inc., West Grove, PA) and an enhanced chemiluminescence detection system (ECL, Amersham Corp.).
[ 3 H] GGOH metabolic labeling of cellular proteins and thinlayer chromatography of lipid extracts NIH3T3 cells transfected with H-Ras-CVLS(61L) were seeded into 12-well plates (200 000 cells/well) and incubated the following day (at 90 ± 100% con¯uency) with tritiated GGOH in a manner similar to that described by Crick et al. (1994) . Cells were incubated with 500 ml DMEM medium containing 30 mCi/ml [1-3 H]GGOH (50 ± 60 Ci/mmole; 0.6 mM GGOH, ®nal), 5% calf serum and 20 mM lovastatin. As noted in the legend to Figure 5 , some cells were treated with additional unlabeled GGOH which increased the ®nal GGOH concentration to 5 mM but decreased the speci®c activity by 8.7-fold. In addition, some cells were pre-treated overnight with 20 mM lovastatin prior to metabolic labeling. After 21 ± 22 h at 378C, the labeling medium was removed and the cells were washed once with 1.5 ml ice-cold PBS, pH 7.5 and harvested using two 1.0 ml aliquots of ice-cold PBS, pH 7.5. The cells were spun down and the pellets were disrupted in ice-cold CH 3 OH. CH 3 OH extracts were removed from the protein pellets and the pellets were extracted twice more with CHCl 3 /CH 3 OH (2 : 1). The extracts for each sample were then combined, concentrated under a stream of N 2 , and 100 000 c.p.m. of each was spotted on Kieselgel 60 silica gel plates (EM Separations, Gibbstown, NJ). The spotted lipid extracts were chromatographed using a n-propanol/ Figure 7 A proposed model depicting the mechanism by which GGOH acts, in the presence of lovastatin, to perserve protein geranylgeranylation and concomitantly potentiate inhibition of protein farnesylation. Dashed lines indicate decreased FPP and GGPP biosynthesis due to the inhibition of HMG-CoA reductase (and, thus, the MVA pathway) by lovastatin. GGOH is taken up by cells and is converted to a metabolite GGX that serves as an inhibitor of FTase and as a substrate for GGTases (only GGTase I shown) 5N NH 4 OH/H 2 O (6 : 1 : 1) solvent system and the labeled products detected by¯uorography using EN 3 Hance (DuPont NEN, Boston, MA). The delipidated protein pellets were air dried and subsequently dissolved in 90 ml SDS ± PAGE sample buer. For each sample, an aliquot (5 ml) was used to determine the amount of tritium incoroporated into protein and 41 ml was loaded onto a 12.5% SDS-polyacrylamide gel. After electrophoretically separating the labeled proteins, the gels were ®xed with CH 3 OH/CH 3 CO 2 H/H 2 O (9 : 2 : 9), treated with ENTENSI-FY (DuPont NEN, Boston, MA), dried down on Whatmam paper, and exposed to X-ray ®lm for 9 days at 7808C.
In vitro GGTase I Assay of 60S Proteins NIH3T3 cells were seeded into 100 mm plates (3.8610 6 cells/ plate) and were treated the following day (about 70% con¯uency) with either vehicle, 25 mM GGOH, 50 mM lovastatin, or 50 mM lovastatin and 25 mM GGOH. After 40 h, the cells were washed, harvested in ice-cold PBS, pH 7.5, and the cell pellet volume (PV) estimated. Cells were disrupted by sonication in 1.46PV of 50 mM TRIS, pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 25mg/ ml leupeptin, and 10 mg/ml aprotinin and the cytosolic (60S) fraction prepared by centrifugation at 25 000 r.p.m. for 1 h at 48C using a Beckman SWTI55 swinging bucket rotor. Equivalent amounts of cytosolic protein (160 mg) were incubated in 50 mM TRIS, pH 7.5, 50 mM ZnCl 2 , 20 mM KCl, 3 mM MgCl 2 , 1 mM DTT with exogenously added human GGTase I (Mono Q-puri®ed from human Burkitt lymphoma (Daudi) cells). Prenylation of 60S proteins was started by addition of 4.8 mCi [
3 H]GGPP and the reaction allowed to proceed for 45 ± 60 min at 378C. Total reaction volume was 55.4 ml. The reaction was stopped by brie¯y placing tubes on ice and then adding 25ml SDS ± PAGE sample buer (2X). Samples were electropheresed on 12.5% SDS-polyacrylamide gels and the gels processed for uorography as described above for [ 3 H]GGOH metabolic labeling.
MTT cytotoxicity assay
NIH3T3 cells transfected with either the H-Ras-CVLS(61L) oncogene or the empty vector were seeded into 96-well plates (10 000/well) and the following day treated (at 50 ± 70% con¯uency) with increasing concentrations of lovastatin (0 ± 300 mM) in the presence or the absence of either 15 mM GGOH or 30 mM ubiquinone (Sigma, St. Louis, MO). After 4 days, the medium was replaced with 100 ml of MTT (1 mg/ ml) in DMEM. After 3 h incubation at 378C, the tetrazolium/formazan reaction was stopped and the uptake of MTT assessed by replacing the medium with 100 ml DMSO, shaking the plate for 5 min to solubilize all the dye, and measuring the absorbance at 492 nm with a Titertek Multiskan spectrophotometer (Flow Laboratories, McClean, VA).
